Research programme: selective estrogen receptor modulators - SRI International

Drug Profile

Research programme: selective estrogen receptor modulators - SRI International

Alternative Names: NSC-732011; SR16158; SR16388

Latest Information Update: 03 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SRI International
  • Class
  • Mechanism of Action Estrogen receptor antagonists; Hypoxia-inducible factor 1 inhibitors; Selective estrogen receptor modulators; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 11 May 2010 Preclinical trials in Multiple myeloma in USA (PO)
  • 11 May 2010 Interim pharmacodynamics data from a preclinical trial in Multiple myeloma released by SRI International
  • 25 Jan 2010 Preclinical development is ongoing the US (http://www.sri.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top